Citadel Advisors’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$307K Buy
10,289
+9,678
+1,584% +$282K ﹤0.01% 10418
2025
Q4
$17.7K Buy
+611
New +$12.3K ﹤0.01% 12365
2025
Q3
Sell
-20,801
Closed -$1.72M 14257
2025
Q2
$1.72M Sell
20,801
-1,206
-5% -$78.4K ﹤0.01% 5999
2025
Q1
$1.74M Sell
22,007
-2,602
-11% -$320K ﹤0.01% 5802
2024
Q4
$4.12M Buy
24,609
+861
+4% +$113K ﹤0.01% 4283
2024
Q3
$2.23M Sell
23,748
-473
-2% -$44.8K ﹤0.01% 5321
2024
Q2
$2.39M Buy
24,221
+599
+3% +$74.7K ﹤0.01% 4990
2024
Q1
$3.63M Hold
23,622
﹤0.01% 4476
2023
Q4
$2.75M Buy
+23,622
New +$3.68M ﹤0.01% 4802
2023
Q1
Sell
-60
Closed -$8.09K 15594
2022
Q4
$8.09K Sell
60
-36
-38% -$7.19K ﹤0.01% 13769
2022
Q3
$19K Buy
+96
New +$30.7K ﹤0.01% 12094
2022
Q2
Sell
-50
Closed -$20.8K 14220
2022
Q1
$29K Buy
50
+14
+39% +$8.32K ﹤0.01% 13121
2021
Q4
$33K Sell
36
-29
-45% -$31.1K ﹤0.01% 13442
2021
Q3
$81K Buy
65
+28
+76% +$54.3K ﹤0.01% 13064
2021
Q2
$116K Buy
+37
New +$146K ﹤0.01% 12781
2020
Q3
Sell
-140
Closed -$875K 10811
2020
Q2
$875K Buy
140
+136
+3,400% +$921K ﹤0.01% 6070
2020
Q1
$42K Buy
+4
New +$62.7K ﹤0.01% 9104
2019
Q1
Sell
-4
Closed -$57K 9926
2018
Q4
$57K Buy
+4
New +$89.5K ﹤0.01% 8457
2018
Q3
Sell
-4
Closed -$130K 9735
2018
Q2
$130K Hold
4
﹤0.01% 8127
2018
Q1
$535K Buy
+4
New +$486K ﹤0.01% 5771

Other funds holding YARW

Citadel Advisors's YARW Position: Q1 2026 in Review

Citadel Advisors increased its Yarrow Bioscience, Inc. Common Stock (YARW) stake by 1,584% in Q1 2026, buying an estimated $282K and bringing the position to 10,289 shares worth $307K. The position accounts for ﹤0.01% of the portfolio, ranked #10418.

Citadel Advisors first reported a position in YARW in Q1 2018 and has held it in 20 quarters since. The position peaked at $4.12M in Q4 2024. 42 funds tracked by Wall St. Rank hold YARW as of Q1 2026.

  • Citadel Advisors held 10,289 shares of Yarrow Bioscience, Inc. Common Stock worth $307K as of Q1 2026.
  • Citadel Advisors bought 9,678 Yarrow Bioscience, Inc. Common Stock shares in Q1 2026, an estimated $282K.
  • Yarrow Bioscience, Inc. Common Stock made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10418 holding.
  • Citadel Advisors first reported a position in Yarrow Bioscience, Inc. Common Stock in Q1 2018 and has held it in 20 quarters since.
  • Citadel Advisors's Yarrow Bioscience, Inc. Common Stock position peaked at $4.12M in Q4 2024.
  • 42 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.